ADXS11-001 immunotherapy targeting HPV-E7: Updated survival and safety data from a

Phase 2 study in Indian women with recurrent cervical cancer

Robert Petit1 and Partha Basu21Advaxis, Inc. Princeton, NJ 2Chittaranjan National Cancer Institute, Kolkata, India

Abstract

Life Cycle of Lm in APC

Lm-LLO Immunotherapy Safety: Frequency of SAEs in 110 patient Phase 2: ADXS11-001 vs. Chemotherapy

Overall Survival

Lm-LLO-E7-15 Best Response Data

ConclusionsCase Study: Patient 110-002

Landmark Survival Duration of Response (PFS)

Overall Survival: Aggressive vs. Non-

Aggressive Disease

Response by Aggressiveness of Disease &

Treatment Group

Lm-LLO-E7-015: A Randomized Phase 2 Study to Assess the Safety & Efficacy of

ADXS-HPV +/- cisplatin Treatment for Recurrent Cervical Cancer

Trial Design: Lm-LLO-E7-15

Safety